Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sarepta Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the safety of its product ELEVIDYS [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Sarepta between June 22, 2023, and June 24, 2025, to discuss their legal rights [1]. - There is a deadline of August 25, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Sarepta [2]. - The complaint alleges that Sarepta and its executives made false statements regarding the safety of ELEVIDYS, which posed significant risks to patients [4]. Group 2: Stock Price Impact - Following a safety update on March 18, 2025, where a patient died after treatment with ELEVIDYS, Sarepta's stock price fell by $27.81, or 27.44%, closing at $73.54 [5]. - On April 4, 2025, after the company disclosed that EU authorities requested a review of the death, the stock price dropped by $4.18, or 7.13%, closing at $54.43 [6]. - A second patient death was reported on June 15, 2025, leading to a significant stock price decline of $15.24, or 42.12%, closing at $20.91 [7][8]. - Following an FDA Safety Communication on June 24, 2025, regarding the investigation of acute liver failure risks, the stock price fell by $1.52, or 8.01%, closing at $17.46 [8][9]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against 3D Systems Corporation for alleged violations of federal securities laws, urging affected investors to contact them before the August 12, 2025 deadline for lead plaintiff applications in a federal class action lawsuit [2][4]. Financial Performance - 3D Systems reported Q4 2024 non-GAAP earnings-per-share of -$0.19, missing consensus estimates by $0.08, with sales revenue of $111 million, a year-over-year decline of 3.4%, and a full-year 2024 sales total of $440.1 million, down 10% from the previous year [5]. - In Q1 2025, the company reported revenue of $94.5 million, an 8% year-over-year decline, and a net loss of $37 million, or $0.28 per share, which is more than double the $16 million loss reported in Q1 2024 [6]. Stock Price Reaction - Following the Q4 2024 results announcement, 3D Systems' stock price fell by $0.57, or 20.96%, closing at $2.15 per share [5]. - After the Q1 2025 results were released, the stock price dropped by $0.68, or 26.6%, to close at $1.87 per share [7]. Allegations of Misconduct - The complaint against 3D Systems alleges that the company and its executives made false or misleading statements regarding the impact of weakened customer spending and overstated the company's resilience in challenging market conditions [4]. - It is also claimed that updated milestone criteria in the United Partnership would negatively affect the revenue from the Regenerative Medicine Program, leading to materially false public statements [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rocket Pharmaceuticals due to misleading statements regarding the safety of its clinical trial for RP-A501, which led to significant investor losses following a serious adverse event [2][4][5]. Group 1: Company Overview - Rocket Pharmaceuticals, Inc. is a publicly traded company on NASDAQ under the ticker RCKT [2]. - The company has faced legal scrutiny following a clinical hold placed by the FDA on its RP-A501 Phase 2 pivotal study due to serious adverse events, including a participant's death [5]. Group 2: Legal Proceedings - A federal securities class action has been filed against Rocket Pharmaceuticals, with a deadline of August 11, 2025, for investors to seek the role of lead plaintiff [2][7]. - The complaint alleges that Rocket provided overly positive statements while concealing material adverse facts about the safety of RP-A501 and the clinical trial protocol [4]. Group 3: Financial Impact - Following the announcement of the FDA's clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in just one trading day [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against PepGen Inc. due to allegations of misleading statements regarding the effectiveness and safety of its drug PGN-EDO51, which has led to significant stock price declines and a federal securities class action [2][4]. Group 1: Allegations and Legal Actions - The complaint against PepGen alleges violations of federal securities laws, including false statements about the effectiveness and safety of PGN-EDO51 and deficiencies in the CONNECT2 study [4]. - Investors who purchased PepGen securities between March 7, 2024, and March 3, 2025, are encouraged to discuss their legal rights and options with Faruqi & Faruqi [1][2]. - The deadline to seek the role of lead plaintiff in the federal securities class action against PepGen is August 11, 2025 [2]. Group 2: Clinical Study Results and Stock Performance - On July 30, 2024, PepGen reported "positive clinical data" from the CONNECT1 study, but analysts noted that the results were below expectations, leading to a 32.69% drop in stock price [5][6]. - Following a clinical hold notice from the FDA on December 16, 2024, due to safety concerns, PepGen's stock fell by 3.63% [7][8]. - A subsequent update on January 29, 2025, regarding safety concerns in the CONNECT1 study led to a further 21.74% decline in stock price [9][10]. - On March 4, 2025, PepGen announced a voluntary pause of the CONNECT2 study, resulting in an 18.86% drop in stock price [10]. - On May 28, 2025, PepGen disclosed that PGN-EDO51 did not achieve target dystrophin levels and decided to discontinue its DMD programs [11].

Core Points - Holzer & Holzer, LLC is investigating Quantum Corporation for potential compliance issues with federal securities laws following the company's inability to file its Annual Report on Form 10-K for the fiscal year ended March 31, 2025 [1] - Quantum disclosed that it is reviewing its accounting related to certain revenue contracts and the application of standalone selling price under applicable accounting standards, which led to a drop in its stock price [1] Company Information - Quantum Corporation trades on NASDAQ under the ticker QMCO [1] - The company has faced scrutiny due to its accounting practices, which may impact investor confidence and stock performance [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in securities litigation, representing shareholders and investors in cases of corporate misconduct [3] - The firm has a history of recovering significant amounts for shareholders affected by fraud, indicating a proactive approach to investor rights [3]

Core Viewpoint - Fortrea Holdings, Inc. is facing a securities class action lawsuit due to allegations of misleading investors regarding its financial projections and business model viability during the class period from July 3, 2023, to February 28, 2025 [3]. Group 1 - The lawsuit claims that Fortrea overstated projected revenue from Pre-Spin Projects, exaggerated expected cost savings from exiting transition service agreements, and inflated EBITDA targets for 2025 [3]. - Investors are reminded of the August 1, 2025 deadline to seek appointment as lead plaintiff in the class action lawsuit [1][4]. - Wolf Haldenstein Adler Freeman & Herz LLP, the law firm handling the case, has over 125 years of experience in securities litigation and aims to protect the rights of investors [4].

Core Viewpoint - Fortrea Holdings Inc. is facing a federal securities class action lawsuit due to allegations of misleading statements regarding its financial performance and business model, particularly concerning its revenue projections and cost savings [5][3]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is investigating potential claims against Fortrea and has set an August 1, 2025 deadline for investors to seek the role of lead plaintiff in the class action [3]. - Investors who suffered losses exceeding $50,000 in Fortrea between July 3, 2023, and February 28, 2025, are encouraged to contact the firm for legal options [1]. Group 2: Allegations Against Fortrea - The complaint alleges that Fortrea overestimated revenue contributions from Pre-Spin Projects and overstated cost savings from exiting Transition Service Agreements (TSAs), leading to inflated EBITDA targets for 2025 [5]. - The company's public statements regarding its business model and financial prospects were deemed materially false and misleading [5]. Group 3: Stock Performance and Analyst Downgrades - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in its business model and a decline in stock price by $2.73 (12.29%) to $19.48 [6]. - Following the cancellation of two scheduled conferences, Baird Equity Research downgraded Fortrea to neutral on December 6, 2024, resulting in a stock price drop of $1.90 (8.06%) to $21.67 [7]. - Fortrea's fourth quarter and full year 2024 results revealed that its revenue and adjusted EBITDA expectations for 2025 were not aligned with prior forecasts, causing a significant stock price decline of $3.47 (25.05%) to $10.38 on March 3, 2025 [8].

Core Viewpoint - A securities class action lawsuit has been filed against 3D Systems Corporation for allegedly making materially false and misleading statements during the Class Period from August 13, 2024, to May 12, 2025 [1][2]. Financial Performance - 3D Systems reported disappointing financial results for Q4 and full-year 2024, with a non-GAAP EPS of -$0.19, missing consensus by $0.08 per share [9]. - Sales revenue for Q4 2024 was $111 million, down 3.4% year-over-year, and missed estimates by $4.17 million [9]. - Full-year 2024 revenue totaled $440.1 million, reflecting a 10% decline from the prior year, primarily due to weaker hardware system sales [9]. - A $9 million revenue reduction in Q4 was attributed to changes in accounting estimates related to the Regenerative Medicine Program [9]. Stock Price Reaction - Following the announcement of disappointing Q4 results on March 26, 2025, shares of 3D Systems fell by 20.96%, closing at $2.15 per share on March 27, 2025 [3]. - After the May 12, 2025 press release regarding Q1 2025 results, the stock price dropped by $0.68 per share, or 26.6%, closing at $1.87 per share on May 13, 2025 [5]. Issues Raised in the Lawsuit - The lawsuit alleges that 3D Systems understated the impact of weakened customer spending and overstated its resilience amid challenging industry conditions [9]. - Revised milestone criteria in the United Partnership are expected to adversely affect revenues from the Regenerative Medicine Program [9]. - The company's public statements were deemed materially misleading due to these factors [9].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in PepGen between March 7, 2024 and March 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 15, 2025 /PRNewswire/ -- Fa ...

Core Viewpoint - Kirby McInerney LLP is investigating potential claims against Hallador Energy Company regarding possible violations of federal securities laws and unlawful business practices [1]. Group 1: Company Developments - On May 23, 2025, Hallador disclosed the termination of its exclusivity agreement with a datacenter developer for a potential power supply deal [1]. - Hallador stated that discussions for an additional exclusivity period are ongoing, along with non-exclusive discussions with other parties [1]. - Following the announcement, Hallador's share price fell by $1.38, from $18.83 on May 22, 2025, to $17.45 on May 23, 2025 [1]. Group 2: Legal Investigation - The investigation by Kirby McInerney LLP focuses on whether Hallador and/or its officers have engaged in unlawful business practices [1]. - Investors who purchased Hallador securities and have information related to the investigation are encouraged to contact the law firm [2].